for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CureVac BV

CVAC.O

Latest Trade

38.58USD

Change

-1.60(-3.98%)

Volume

456,955

Today's Range

38.25

 - 

39.64

52 Week Range

37.54

 - 

151.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
40.18
Open
39.45
Volume
456,955
3M AVG Volume
14.63
Today's High
39.64
Today's Low
38.25
52 Week High
151.80
52 Week Low
37.54
Shares Out (MIL)
186.60
Market Cap (MIL)
7,497.58
Forward P/E
-13.80
Dividend (Yield %)
--

Next Event

CureVac NV Annual Shareholders Meeting

Latest Developments

更多

German Economy Ministry Says Government To Retain Curevac Holding

Dievini Explains Reasons For Changes In Shareholdings In CureVac

EMA Ends Rolling Review Of CureVac COVID-19 Vaccine After Withdrawal By Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CureVac BV

CureVac AG is a Germany-based biotechnology company. The Company is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The Company's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

Industry

Biotechnology & Drugs

Contact Info

Friedrich-Miescher-Str. 15

72076

Germany

+49.7071.98830

Executive Leadership

Baron Jean Stephenne

Independent Chairman of Supervisory Board

Franz-Werner Haas

Chief Executive Officer, Chief Operating Officer, Member of the Management Board

Friedrich von Bohlen und Halbach

Vice Chairman of the Supervisory Board

Pierre Kemula

Chief Financial Officer, Member of the Management Board

Mariola Fotin-Mleczek

Chief Technology Officer, Member of the Management Board

Key Stats

2.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2020

0.0K

2021(E)

0.1K
EPS (EUR)

2020

-0.980

2021(E)

-2.473
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.77
LT Debt To Equity (MRQ)
7.32
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up